This is not the latest version of this item. The latest version can be found at: https://scientiasalut.gencat.cat/handle/11351/1278
Neuroblastoma is one of the most frequent types of solid tumour in children, especially in the first year of life, where this type of tumour accounts for 50% of all tumours. It is the second cause of death in children after accidents. The objective of this work was to analyse available scientific knowledge regarding the anti-GD monoclonal antibody in the treatment of patients with high risk neuroblastoma and to assess the possibility of performing this treatment in a reference centre in our country or the inclusion of these patients in international multicenter clinical trials currently underway. A systematic review of the scientific evidence up until 2008 regarding the efficacy, effectiveness and safety of anti-GD2 monoclonal antibodies in the treatment of patients with high risk neuroblastoma was carried out. Internal validity and the grade of recommendation of the studies were assessed by two reviewers using Scottish Intercollegiate Guidelines Network (SIGN) criteria. A qualitative synthesis of the scientific evidence was performed.
Cancer in children; Immunotherapy; Evidence-based medicine
Oliva G, Paladio N. Inmunoterapia anti-GD2 en pacientes con neuroblastoma de alto riesgo. Barcelona: Ministerio de Ciencia e Innovación; 2010.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/1278.1
This item appears in following collections
The following license files are associated with this item: